Every 8-K that Joint Corp (JYNT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow JYNT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full JYNT filings page.
The Joint Corp., a chiropractic clinic franchisor, reported second quarter 2026 results reflecting its shift to a capital-light, pure-play franchisor model. Revenue from continuing operations was $15.2 million, up 14% year over year, while reported system-wide sales were $180.0 million, down 3.7%, and comp sales were (2.8)%.
Consolidated net income increased to $653,000 and net loss from continuing operations narrowed to $251,000 compared with a $1.0 million loss a year earlier. Adjusted EBITDA from continuing operations rose to $1.5 million from $88,000. Cash flow from operating activities improved to $2.2 million and free cash flow to $1.9 million.
The network had 941 clinics at June 30, 2026, reflecting openings, closures and refranchising under the Joint 2.0 strategy. Unrestricted cash totaled $22.2 million, and the company has an undrawn $20 million credit line. Management reaffirmed 2026 guidance, including system-wide sales of $519–$552 million, system-wide comp sales between (3)% and 3%, and consolidated Adjusted EBITDA of $12.5–$13.5 million.
The Joint Corp. reported results from its 2026 annual stockholder meeting held on May 20, 2026. Stockholders elected seven directors to serve until the 2027 annual meeting, with each nominee receiving over 9.8 million votes in favor and substantial support relative to votes against.
Stockholders approved, on an advisory basis, the compensation of the company’s named executive officers and supported holding this advisory vote on executive pay every year. They also ratified the appointment of BDO USA, P.C. as independent registered public accounting firm for the year ending December 31, 2026, with more than 12.7 million votes in favor.
The Joint Corp. reported stronger first-quarter 2026 results while amending its credit facility and advancing its refranchising strategy. Revenue from continuing operations rose 13% to $14.8 million, and consolidated net income increased 34% to $1.3 million, or $0.09 per diluted share. Net income from continuing operations was $1.1 million, a turnaround from a loss of $0.5 million a year earlier, and consolidated Adjusted EBITDA grew 22% to $3.5 million.
System-wide sales were $126.1 million, down 4.9%, with comp sales down 4.2%. Free cash flow improved to $(1.7) million from $(4.0) million, and unrestricted cash totaled $20.7 million with a fully undrawn $20 million credit line. The company repurchased 137,000 shares for $1.1 million.
The company signed an agreement to sell 45 company-owned or managed clinics and a letter of intent to sell five more, leaving only three clinics company-owned or managed after completion. It reiterated 2026 guidance for system-wide sales of $519–$552 million, consolidated Adjusted EBITDA of $12.5–$13.5 million, and 30–35 new franchised clinic openings.
The Joint Corp. has signed and begun executing an Asset Purchase Agreement to sell 45 company-owned or managed clinics in Southern California to Elite Chiro Group for approximately $2.3 million. On April 27, 2026, ownership of 13 clinics transferred, while Elite Chiro Group assumed operations of the remaining 32 clinics under a Management Service Agreement until lease assignments are completed.
Upon completion of this transaction and two previously announced refranchising agreements, the company expects to operate only three corporate-managed clinics out of 960 locations, effectively shifting to a capital-light, pure-play franchisor model focused on supporting franchisee growth.
The Joint Corp. signed an Asset Purchase Agreement to sell the assets of, and grant franchise rights for, 45 company-owned or managed clinics in Southern California to Elite Chiro Group for an aggregate purchase price of $2.3 million, subject to adjustments.
The price includes prorated franchise fees across 45 new franchise agreements and non-exclusive development rights for 10 additional clinics in agreed metropolitan areas. Elite Chiro Group will pay a non-refundable $150,000 down payment for exclusivity, with the remaining amount placed in escrow and released as each clinic closes. Each clinic closing depends on assignment of its existing lease and other customary closing conditions.
The Joint Corp. reported a return to profitability for 2025 while accelerating its shift to a franchisor model. Full-year revenue rose to $54.9 million from $52.2 million, with consolidated net income improving to $2.9 million from a loss of $5.8 million. Consolidated Adjusted EBITDA increased 13.9% to $13.0 million.
In the fourth quarter, revenue grew 3.1% to $15.2 million and net income reached $1.0 million. System-wide sales for 2025 were $532.4 million, though comp sales declined 0.4%. The company refranchised 41 clinics, ended the year with 960 locations, and repurchased 1.3 million shares for $11.3 million.
For 2026, guidance calls for system-wide sales between $519 million and $552 million, system-wide comp sales between (3)% and 3%, consolidated Adjusted EBITDA of $12.5–$13.5 million, and 30–35 new franchised clinic openings as it completes its transition to a capital-light, pure-play franchisor model.
The Joint Corp. filed an amended current report to correct its description of a letter agreement with Bandera Partners LLC and Jefferson Gramm. Under the revised summary, the company agreed to include Mr. Gramm in its slate of director nominees for the 2026 annual meeting and to recommend that stockholders vote for his election. Bandera agreed that, until a defined termination date, it will not increase its beneficial ownership above the 3,937,296 shares of common stock it already holds, excluding any equity awards tied to Mr. Gramm’s board service. The agreement lasts until the earlier of thirty days before the nomination notice deadline for the 2027 annual meeting or January 21, 2027.
The Joint Corp. reported entering into a letter agreement on January 5, 2026 with Bandera Partners LLC and Jefferson Gramm. Under this agreement, the company will include Mr. Gramm in its slate of nominees for election to the board of directors at the 2026 annual meeting of stockholders and will recommend that stockholders vote in favor of his election.
The agreement also contains voting commitments and standstill obligations for Bandera, along with restrictions on transfers of Joint Corp. common stock held by Bandera until the agreement ends. The letter agreement will remain in effect until the earlier of thirty days before the director nomination deadline for the 2027 annual meeting or January 21, 2027.
The Joint Corp. (JYNT) entered a material definitive agreement to sell the assets of, and grant franchise rights to, 45 company-owned or managed clinics in Southern California to Elite Chiro Group for an aggregate purchase price of $4.5 million, subject to adjustments. The price includes $3,154,500 in cash and $1,345,500 in prorated franchise fees across 45 franchise agreements. Elite Chiro Group will pay a $100,000 non-refundable down payment for exclusivity, with the balance due at closing; if unpaid at closing, the balance will convert into a secured promissory note maturing 60 days from signing.
The transaction is expressly conditioned on assigning existing leases for at least 38 of the 45 clinics or executing specified management agreements, along with customary closing conditions. In connection with the deal, The Joint will acquire non-exclusive development rights for 10 clinics, with a $90,000 development fee. Separately, the Board authorized an additional $12.0 million under the stock repurchase program and extended it through November 4, 2027.
JOINT Corp (JYNT) entered a consent and third amendment to its existing credit agreement with JPMorgan Chase Bank, N.A. on September 30, 2025. The amendment expressly consents to the company's refranchising of all company-owned or managed clinics and extends the maturity date of the company's revolving credit facility to August 31, 2027. The amendment includes customary representations, warranties, and conditions precedent. The filing notes the 2025 Amendment is attached as Exhibit 10.1 and that the short description provided is qualified in its entirety by the full amendment text.
The company disclosed the departure of its Chief Financial Officer, Mr. Singleton, whose role ceased effective June 9, 2025. The company and Mr. Singleton entered a separation agreement dated August 22, 2025 that includes a general release and a revocation period. If not revoked, the agreement provides Separation Benefits: a cash payment equal to six months of base salary, a cash payment for accumulated time off of $36,193.99, an additional cash payment of $15,000, reimbursement for accrued expenses per company policy, and payment of up to six months of COBRA health-insurance cost if elected. Outstanding equity awards will be governed by existing award agreements and plans and will not receive accelerated vesting under the Separation Agreement.
Joint (NASDAQ:JYNT) agreed to sell the assets of 31 company-owned clinics in Arizona and New Mexico to Joint Ventures, LLC for $11.07 million, with closing targeted on or before 30 Jun 2025 and customary conditions attached. In return, the company will obtain regional developer rights covering 46 existing franchised clinics and 30 future development sites across Northern California, Utah, Nevada, Washington and Oregon, enlarging its franchise pipeline.
In a separate transaction, the company divested five clinics in Kansas and Missouri to 93 Chiro, LLC. Management positions both deals as part of a strategic shift toward an asset-light, royalty-driven model that increases liquidity, cuts operating costs and accelerates unit growth.